RecruitingNCT05106387

An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant

A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With Vonsetamig (BCMA x CD3 Bispecific Antibody) Who Receive a Kidney Transplant

Sponsor

Regeneron Pharmaceuticals

Enrollment

20 participants

Start Date

Oct 19, 2023

Study Type

OBSERVATIONAL

Conditions

Chronic Kidney Disease(CKD)

Summary

The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This is an observational follow-up study for people who received a kidney transplant while participating in an earlier clinical trial testing a drug called vonsetamig, to track their long-term health and outcomes after transplant. **You may be eligible if...** - You received at least one dose of vonsetamig in the parent study (NCT05092347) - You received a kidney transplant while enrolled in that study - You are willing and able to attend follow-up visits and follow study procedures - You are able to provide informed consent **You may NOT be eligible if...** - There are no exclusion criteria — all eligible participants from the parent study may enroll Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNoninterventional

No investigational treatment will be given in this noninterventional extension study

Locations(9)

Cedars-Sinai Medical Center

Los Angeles, California, United States

University of California Irvine

Orange, California, United States

Connie Frank Transplant Center at UCSF

San Francisco, California, United States

Yale University of Medicine

New Haven, Connecticut, United States

Comprehensive Transplant Center

Chicago, Illinois, United States

John Hopkins Hospital

Baltimore, Maryland, United States

University of Minnesota

Minneapolis, Minnesota, United States

New York University Langone Health

New York, New York, United States

Penn Transplant Institute

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05106387

Related Trials

Kidney Function in People With Cystic Fibrosis in the Era of HEMT

NCT065954203 locations

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

NCT0509234710 locations

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

NCT069066276 locations

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

NCT069066406 locations

Exercise and Monitoring With Post-Hospitalization Muscle Atrophy to Sustain Intrinsic Capacity and Strength

NCT066079132 locations